Long-term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 5, 2013, Pages 636-647

  López, Esther ^a   Berna Erro, Alejandro ^a   Bermejo, Nuria ^c   Brull, José María ^d   Martinez, Rocío ^b   Garcia Pino, Guadalupe ^b   Alvarado, Raul ^b   Salido, Ginés María ^a   Rosado, Juan Antonio ^a   Cubero, Juan José ^b   Redondo, Pedro Cosme ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

^c San Pedro de Alcántara Hospital Clinical Neurophysiology   (Spain)

^d Extremadura County Blood Donation Center   (Spain)

Author keywords

Calcium; mTOR; Platelets; Rapamycin; Thrombosis

Indexed keywords

CALCIUM; DRUG DERIVATIVE; EVEROLIMUS; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HOMEOSTASIS; HUMAN; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; TIME;

ADULT; AGED; BLOOD PLATELETS; CALCIUM; DEMOGRAPHY; ENZYME ACTIVATION; FEMALE; HOMEOSTASIS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHORYLATION; PLATELET AGGREGATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

MAMMALIA; STREPTOMYCES HYGROSCOPICUS;

EID: 84878361255     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12044     Document Type: Article

References (54)

1. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22: 159-68.
2. Pereira MJ, Palming J, Rizell M, et al. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. Mol Cell Endocrinol. 2012; 355: 96-105.
3. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994; 369: 756-8.
4. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098-101.
5. Sarbassov DD, Peterson CA. Insulin receptor substrate-1 and phosphatidylinositol 3-kinase regulate extracellular signal-regulated kinase-dependent and -independent signaling pathways during myogenic differentiation. Mol Endocrinol. 1998; 12: 1870-8.
6. Laudanski P, Kowalczuk O, Klasa-Mazurkiewicz D, et al. Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer. Folia Histochem Cytobiol. 2011; 49: 317-24.
7. Liu L, Chen L, Luo Y, et al. Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS ONE. 2010; 5: e10578.
8. Hsieh AC, Costa M, Zollo O, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010; 17: 249-61.
9. Rossi G, Cavazza A, Graziano P, et al. mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Am J Respir Crit Care Med. 2012; 185: 341.
10. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005; 16: 525-37.
11. Donnelly JG, Soldin SJ. Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. Clin Biochem. 1994; 27: 367-72.
12. Deivanayagam CC, Carson M, Thotakura A, et al. Structure of FKBP12.6 in complex with rapamycin. Acta Crystallogr D Biol Crystallogr. 2000; 56: 266-71.
13. Kozany C, Marz A, Kress C, et al. Fluorescent probes to characterise FK506-binding proteins. ChemBioChem. 2009; 10: 1402-10.
14. Facchinetti V, Ouyang W, Wei H, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008; 27: 1932-43.
15. Rosado JA, Pariente JA, Salido GM, et al. SERCA2b activity is regulated by cyclophilins in human platelets. Arterioscler Thromb Vasc Biol. 2010; 30: 419-25.
16. 2+-ATPase by macrocyclic lactones and cyclosporin A. Biochem J. 2002; 366: 255-63.
17. 2+ pump in neurons. J Biol Chem. 2000; 275: 3706-12.
18. Genazzani AA, Carafoli E, Guerini D. Calcineurin controls inositol 1, 4, 5-trisphosphate type 1 receptor expression in neurons. Proc Natl Acad Sci USA. 1999; 96: 5797-801.
19. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006; 12: 5165-73.
20. Yost SE, Byrne R, Kaplan B. Transplantation: mTOR inhibition in kidney transplant recipients. Nat Rev Nephrol. 2011; 7: 553-5.
21. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006; 82: 1153-62.
22. Lippi U, Schinella M, Modena N, et al. Unpredictable effects of K3 EDTA on mean platelet volume. Am J Clin Pathol. 1987; 87: 391-3.
23. Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol. 1990; 52: 431-49.
24. Sage SO, Brownlow SL, Rosado JA. TRP channels and calcium entry in human platelets. Blood. 2002; 100: 4245-6; author reply 6-7.
25. 3 receptor and SERCA3 in human platelets. Biochim Biophys Acta. 2008; 1783: 1163-76.
26. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985; 260: 3440-50.
27. Robinson M, MacHin S, Mackie I, et al. In vivo biotinylation studies: specificity of labelling of reticulated platelets by thiazole orange and mepacrine. Br J Haematol. 2000; 108: 859-64.
28. Pihusch R, Wegner H, Salat C, et al. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002; 30: 381-7.
29. Deb S, Patra HK, Lahiri P, et al. Multistability in platelets and their response to gold nanoparticles. Nanomedicine. 2011; 7: 376-84.
30. Whiss PA, Andersson RG, Srinivas U. Modulation of P-selectin expression on isolated human platelets by an NO donor assessed by a novel ELISA application. J Immunol Methods. 1997; 200: 135-43.
31. 2+ entry: vesicle fusion or reversible trafficking and de novo conformational coupling? J Cell Physiol. 2005; 205: 262-9.
32. 2+ entry in mouse pancreatic acinar cells. Am J Physiol Cell Physiol. 2005; 288: C214-21.
33. Redondo PC, Harper MT, Rosado JA, et al. A role for cofilin in the activation of store-operated calcium entry by de novo conformational coupling in human platelets. Blood. 2006; 107: 973-9.
34. Ekim B, Magnuson B, Acosta-Jaquez HA, et al. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol. 2011; 31: 2787-801.
35. Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, et al. Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). Cell Cycle. 2011; 10: 3140-52.
36. 2+ compartments show differential sensitivity to thrombin, ADP and vasopressin in human platelets. Cell Signal. 2006; 18: 373-81.
37. 2+ stores in platelets, as identified by their differential sensitivity to 2, 5-di-(tert-butyl)-1, 4-benzohydroquinone and thapsigargin. Biochem J. 1995; 310(Pt 2): 449-52.
38. 2+ ATPase system in human platelets. Br J Haematol. 1997; 97: 192-203.
39. Ramstrom AS, Fagerberg IH, Lindahl TL. A flow cytometric assay for the study of dense granule storage and release in human platelets. Platelets. 1999; 10: 153-8.
40. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004; 103: 2096-104.
41. Berna MJ, Tapia JA, Sancho V, et al. Gastrointestinal growth factors and hormones have divergent effects on Akt activation. Cell Signal. 2009; 21: 622-38.
42. Moore SF, Hunter RW, Hers I. mTORC2 protein complex-mediated Akt (Protein Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets [corrected]. J Biol Chem. 2011; 286: 24553-60.
43. 2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009; 297: L666-76.
44. 2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 2012; 302: C405-11.
45. Wu Q, Huang KS, Chen M, et al. Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro. Platelets. 2009; 20: 428-31.
46. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284: 8023-32.
47. Aslan JE, Tormoen GW, Loren CP, et al. S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood. 2011; 118: 3129-36.
48. Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem. 1996; 271: 10811-5.
49. Weyrich AS, Denis MM, Schwertz H, et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood. 2007; 109: 1975-83.
50. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000; 69: 2085-90.
51. Johnson EM, Zimmerman J, Duderstadt K, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 1996; 28: 987.
52. Raslova H, Baccini V, Loussaief L, et al. Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood. 2006; 107: 2303-10.
53. Chanprasert S, Geddis AE, Barroga C, et al. Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes. Cell Signal. 2006; 18: 1212-8.
54. Liu ZJ, Italiano J Jr, Ferrer-Marin F, et al. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. Blood. 2011; 117: 4106-17.